Rastislav Bahleda

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Christophe Massard, Stefan Michiels, Charles Ferté et al. · Cancer Discovery · 2017 · 776 citations

Medicine, Molecular Biology, Oncology +17

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann et al. · Journal of Clinical Oncology · 2015 · 384 citations

Medicine, Pharmacokinetics, Pharmacology +14

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i> / <i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study

Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro et al. · Cancer Discovery · 2021 · 248 citations · Full text

Medicine, Oncology, Pharmacology +10

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Rastislav Bahleda, Antoîne Italiano, Cinta Hierro et al. · Clinical Cancer Research · 2019 · 244 citations · Full text

Medicine, Oncology, Pharmacology +14

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Frédéric Bigot, Eduardo Castañón, Capucine Baldini et al. · European Journal of Cancer · 2017 · 225 citations

Life Sciences, Immunology, Oncology +12